Inactive

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other th... This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with JPT Peptide Technologies GmbH (“JPT”). National Institute of Allergy & Infectious Diseases (NIAID)’s Vaccine Research Center (VRC) (collectively “Program”) is engaged in studies to understand the pathology, progression, and disease mechanisms of COVID-19 by better understanding the underlying immunologic response with the hope of justifying the use of specific vaccines and vaccine dosing regiments as well as dosing methods (intramuscular, intra-nasal, etc.) These studies allow policy decisions to be made about future directions of research regarding changing vaccine formulation and boosting frequency. In order to accomplish this, certain types of reagents are used to examine blood and tissue derived immune cell subtypes and the cytokines they produce in animal studies where specimens have been exposed COVID-19. The samples acquired from these studies will be analyzed both pre- and post-vaccination and pre- and post-infection. Deviation from these qualified reagents will require substantial person-hours to recertify new reagents and will also forfeit consistency with previous studies related to the ongoing research. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following: 1. PepMix SARS-CoV-2 (Spike Glycoprotein) – Qty 20x Product ID: PM-WCPV-S-1 Protein ID: P0DTC2 Mix of 158+157 peptides (15mers, overlap 11) Peptide purity: crude (Major peak by LC-MS is guaranteed to be peptide of interest) 2 vials (15 nmol per peptide, appr. 25 ug per peptide) 2. PepMix SARS-CoV-2 (NCAP) – Qty 25x Product ID: PM-WCPV-NCAP-1 Protein ID: P0DTC9 Mix of 102 peptides (15mers, overlap 11) Peptide purity: crude (Major peak by LC-MS is guaranteed to be peptide of interest) 1 vial (15 nmol per peptide, appr. 25 ug per peptide) Delivery will occur within three (3) weeks of award. Place of Performance or Delivery: Bethesda, MD 20892. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2151724 by 4:00 pm eastern standard time on 05/15/2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.